PHASE I TRIAL OF INTRAVENOUS FENRETINIDE (4-HPR) FOR PATIENTS WITH HEMATOLOGI

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项使用加速滴定设计的静脉注射芬维甲素(4-HPR)治疗恶性血液病患者的I期试验。芬维奈德已经在口服制剂中进行了试验，用于治疗成人乳腺癌和卵巢癌，以及儿童神经母细胞瘤。口服药物的生物利用度较低，无法达到对白血病和淋巴瘤细胞系具有直接肿瘤细胞毒性的血清水平。这项I期试验将评估一种新的芬维甲酸静脉注射脂肪乳剂对恶性血液病患者的安全性、可行性和毒性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase I Trial of Intravenous Fenretinide (4-HPR) for patients with Hematologic Malignancies using an accelerated titration design. Fenretinide has been tested in oral formulation in treatment of breast and ovarian cancer in adults, and in neuroblastoma in children. Poor bioavailability of the oral drug precludes reaching serum levels shown to have direct tumor cytotoxicity for leukemia and lympoma cell lines. This phase I trial will assess safety, feasibilty, and toxicity of a new intravenous lipid emulsion formulation of fenretinide in patients with Hematologic Malignancies.